

<b>Reference number(s)</b>
1779-H

## SPECIALTY QUANTITY LIMIT PROGRAM

### Juxtapid (lomitapide) Kynamro (mipomersen)

#### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

#### II. COVERED QUANTITIES

Medication	FDA-recommended dosing	Standard Limit
Juxtapid 5 mg Capsule	Maximum of 60 mg daily	28 per 28 days
Juxtapid 10 mg Capsule	Maximum of 60 mg daily	28 per 28 days
Juxtapid 20 mg Capsule	Maximum of 60 mg daily	28 per 28 days
Juxtapid 30 mg Capsule	Maximum of 60 mg daily	28 per 28 days
Juxtapid 40 mg Capsule	Maximum of 60 mg daily	28 per 28 days
Juxtapid 60 mg Capsule	Maximum of 60 mg daily	28 per 28 days
Kynamro 200 mg/ml Injection	200 mg once weekly	4 per 28 days

#### III. REFERENCES

1. Juxtapid [package insert]. Cambridge, MA: Aegerion Pharmaceuticals, Inc; August 2017.
2. Kynamro [package insert]. Cambridge, MA: Genzyme Corporation, Inc; May 2016.